Pfizer Inc. news

   Watch this stock
Showing stories 1 - 10 of about 183   

Articles published

PFE 29.57 -0.20 (-0.67%)
price chart
Should Pfizer Inc. Buy Actavis plc?
Earlier this year, a media circus erupted over Pfizer's reported interest in AstraZeneca (NYSE: AZN ) . The deal would have exceeded $100 billion and created a company roughly the same size as Johnson & Johnson. AstraZeneca brass, however, felt the ...
Pfizer Inc. Is Kicking The Tires At Actavis PLC  Benzinga
Pfizer Said to Approach Actavis to Gauge Interest in Deal  Bloomberg
Related articles »  
Pfizer Inc. Stock Fails To Break Out: Is It Headed Back Down?
Pfizer Inc. (NYSE: PFE) shareholders have experienced the short-term euphoria of seeing their stock rally a massive 10 percent from August to September.
Related articles »  
Stocks Alert: Pfizer Inc. (NYSE:PFE), Angie's List Inc (NASDAQ:ANGI), Oncomed ...
Pfizer Inc. (NYSE:PFE) and Kyowa Hakko Kirin said late on Monday they signed an agreement to study the therapeutic potential of combining Pfizer's PF-05082566 antibody with Kyowa Hakko Kirin's anti-CCR4 antibody mogamulizumab in a Phase Ib clinical ...
Better Dividend Stock: Johnson & Johnson or Pfizer, Inc?
According to Susanna Kim of ABC News, dividend yield and dividend growth comprised 90% of the total nominal returns for investors in the S&P 500 between 1910 and 2010.
Pfizer Inc.: Pfizer And Kyowa Hakko Kirin To Collaborate On Immuno-Oncology ...
NEW YORK & TOKYO--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) and Kyowa Hakko Kirin (Tokyo:4151), announced today that they have entered into an agreement to explore the therapeutic potential of the combination of Pfizer's PF-05082566, ...
Related articles »  
Fast Money Picks For September 26 - Pfizer Inc., The Dow Chemical Company ...
CNBC Fast Money's Pete Najarian said on the show that he likes big pharmaceutical names. He wants to buy Pfizer Inc. (NYSE: PFE) on Friday.
Related articles »  
Can Pfizer Grow Without A Big Acquisition?
With the deal likely off the table, investors need to evaluate whether Pfizer can grow without a big acquisition. Growth in its existing portfolio, combined with stronger profitability and fundamentals give the company the resources to provide a good ...
Pfizer Announces Positive Data For Cancer Drug Xalkori
Pfizer Inc. (PFE) announced extended Phase I trial results for Xalkori (crizotinib) at the European Society for Medical Oncology (ESMO) meeting on Saturday.
Pfizer drug effective in patients with rare lung cancer: Study  Economic Times
Related articles »  
Why I'd Avoid Pfizer Inc. Stock Despite the Dividend
Pfizer's problem in the clinic is uncertainty regarding its ability to generate new blockbuster drugs. The company decided, along with almost every other Big Pharma simultaneously, to go after novel oncology and high cholesterol drugs to replace former ...
Related articles »  
Market Movers: AT&T, Inc. (NYSE:T), Pfizer Inc. (NYSE:PFE), Pacific Ethanol ...
Pfizer Inc. (NYSE:PFE) said it is showing positive results against rare genetic mutation in the ROS1 gene, according to a report presented by Pfizer at medical meeting, on Saturday.
Related articles »